Can deregulation drive alpha? Joseph Castiglie thinks so-and he's betting on it
This interview was originally prepared and conducted by ETF Central and is reprinted here with permission.
In this edition of Ask the Manager, ETF Central caught up with Joseph Castiglie, COO and CIO of SYKON Asset Management, to unpack the strategy behind The Free Markets ETF (FMKT).
How do you turn deregulation into alpha?
Castiglie walks us through SYKON’s approach, focusing on sectors like energy, financials, and healthcare, where policy shifts can have a material impact.
By combining active management with tools that track regulatory momentum, the team aims to identify companies best positioned to benefit from a changing policy landscape.
What is your role, and your firm’s role, within the FMKT ETF?
SYKON Asset Management is one of the three sub-advisers of The Free Markets ETF (Ticker: FMKT), where we work with the fund adviser to maintain an actively managed portfolio that capitalizes on free markets and deregulation.
As one of the portfolio managers, I aim to identify investment opportunities from changes in the regulatory environment, while maintaining an active, risk managed portfolio construction process.
What are the levers that the Trump administration can use to promote economic growth in his second term?
There are several sectors that can have an outsized effect in promoting economic growth throughout this term.
Easing capital requirements for banks would allow them to deploy more capital for business investment, while potentially lowering capital costs due to increased liquidity in the system.
Additionally, several executive orders aim to reshape the nuclear landscape in the US, which can enhance the stability and availability of our energy grid, lowering costs for consumers and companies alike, as the expectations for increased demand rise in the face of the growing use of AI and data centers.
What is the impact of regulation on the American economy?
The amount of Federal regulation has steadily grown for decades, regardless of the political party in the White House. This regulation costs an estimated $2.1 trillion annually or roughly $15,000 per household.
A hidden cost of this increasing burden is the missed opportunity cost stemming from fewer people choosing an entrepreneurial path as a small business owner.
Why would the impact of regulation be different now versus prior attempts to reduce the regulatory burden in the American economy? What is the specific difference today?
In July of last year, the Supreme Court overturned the Chevron Doctrine, in which Federal agencies were given some degree of deference by the courts in their ability to interpret and enforce Federal regulations, a ruling Chief Justice Roberts said was incompatible with the courts’ fundamental duty to interpret the law.
This change could effectively undermine Federal regulators in their efforts to enforce vague or unclear laws, while systematically opening the door to numerous legal challenges to prior court cases that relied on the Chevron Doctrine since its establishment in 1984.
How can you quantify a company’s ability to benefit from changes in regulatory policy?
We start by targeting industries with high regulatory cost burdens and then score companies based on a range of financial metrics, such as operating margin and SG&A efficiency, to better understand their potential to benefit from reduced regulation.
The logic behind this is that companies that can efficiently manage operations despite higher regulatory expense will likely achieve even greater efficiency when those costs decline.
Are there specific sectors you expect to benefit from deregulation more than others?
In an earlier question, I addressed the potential for benefits in both the financial and energy sectors, both of which I believe are particularly leveraged to lower regulation.
Health care would be another sector that could experience significant gains from deregulation, as many executive orders have been issued that will bring changes that streamline FDA approvals, revise Medicare Drug Price Negotiation rules, and provide incentives for domestic manufacturing.
What tools are you using to measure a company’s momentum with respect to policy changes?
We’ve developed an AI screening tool, our R2Q system, to cross-check corporate filings, earnings calls, and policy databases for direct regulatory tailwinds and policy momentum.
As the pace of deregulation has increased, this has allowed us to analyze an increasing number of data points to specifically target and rank companies that exhibit a higher propensity to benefit from deregulation.
What are a few of your top holdings in the fund?
Well, three of our top holdings reflect the sectors that I had highlighted in the prior questions – financials, energy, and healthcare.
In the financial space, we have RobinHood (Ticker: HOOD), which we believe is uniquely positioned to benefit from recent executive orders that affect crypto currencies and digital assets, as well as AI deployment in the fintech space.
In the energy sector, we have Uranium Energy Corp (Ticker: UEC), which stands to benefit from faster reactor approvals and advances in the deployment of small modular reactors.
Lastly, we have McKesson (Ticker: MCK) in the healthcare sector, which could see tremendous benefits from streamlined FDA approvals and domestic manufacturing incentives.
About Joseph P. Castiglie III, CFA
Joseph Castiglie is the COO and CIO of SYKON, where he leads investment strategy and operations, focusing on portfolio optimization and risk management using disciplined portfolio management techniques that integrate traditional financial theory and the principles of behavioral finance.
In his role as Portfolio Manager of the Free Markets ETF (FMKT), Joe uses financial and market data to identify investment opportunities that may arise from regulatory changes and macroeconomic trend shifts.
Joe maintains a focus on delivering clear and actionable insights that are guided by disciplined, process-oriented risk management, whether he is managing an investment mandate for a public ETFs or managing private client assets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.